NCT07052032Active, not recruitingPhase 1
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- First submitted
- 18 Jun 2025
- Start date
- 16 Jun 2025
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Candid Therapeutics
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07052032
- EU CT number
- 2025-523265-15-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 47
- From 16 Jun 2025 to the primary completion date, 1 Jun 2027
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receipt of or inability to discontinue any excluded therapies
- Receipt of live vaccine within 4 weeks
- Presence of any concomitant autoimmune disease
- APS or thrombotic event not adequately controlled by anticoagulation therapy
- Presence of 1 or more significant concurrent medical conditions
- Major surgery requiring use of general anesthesia within 12 weeks or planned or expected major surgery during the study
Other illness
- Active infection
- Active or known history of catastrophic anti-phospholipid syndrome
- History of progressive multifocal leukoencephalopathy
- Central nervous system disease
- Have a diagnosis or history of malignant disease within 5 years
- Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair ability to receive planned treatment or to understand informed consent
- History of or planned organ transplant and/or autologous or allogeneic hematopoietic stem cell transplantation
Lab values
- Inadequate clinical laboratory parameters at Screening
Other
- Women who are pregnant or breastfeeding
- Patients who do not agree to the use of highly effective contraception as defined by the protocol
Who the study is looking for
- 18 to 75 years old
- Diagnosis of adult-onset RA
- Class I-III RA
- Moderately to severely active RA
- Inadequate treatment response as defined in the protocol
- Stable use of any concomitant therapies
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Candid Clinical Site Coordinator of this site? Confirm its status | Chisinau | Moldova | Unknown status |
| Arensia Clinics S.R.L. Coordinator of this site? Confirm its status | Bucharest | Romania | Completed |
| Spitalul Clinic Judetean De Urgenta Cluj Coordinator of this site? Confirm its status | Cluj-Napoca | Romania | Completed |
| Candid Clinical Site Coordinator of this site? Confirm its status | Kyiv | Ukraine | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.